Corrosion inhibitors and methods for reducing or inhibiting corrosion of metals in aqueous systems are provided. Corrosion inhibitor compositions may include tetracarboxylic acids, such as butane tetracarboxylic acid. The compositions may include other components, such as zinc, molybdate, silicate, cerium, among others. The compositions may also include polymers or oligomers. The corrosion inhibitor compositions produced synergistic results and unexpectedly low corrosion rates.

Corrosion inhibitors and methods for reducing or inhibiting corrosion of metals in aqueous systems are provided. Corrosion inhibitor compositions may include tetracarboxylic acids, such as butane tetracarboxylic acid. The compositions may include other components, such as zinc, molybdate, silicate, cerium, among others. The compositions may also include polymers or oligomers. The corrosion inhibitor compositions produced synergistic results and unexpectedly low corrosion rates.

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.

The present disclosure provides a pressure-reducing and injection-enhancing anti-scaling agent for low-permeability water-injection wells and a preparation method thereof. The anti-scaling agent is prepared from starting materials comprising: 10 to 12 parts of non-ionic surfactant(s), 18 to 20 parts of hexasodium triethylenetetramine-N,N,N,N,N,N-hexaacetate, 5 to 8 parts of anionic surfactant(s), 6 to 8 parts of an organic phosphonic acid-carboxylic acid scale inhibitor, 2 to 5 parts of a dispersant, 15 to 18 parts of a diluent, 8 to 10 parts of an organic amine salt, and 30 to 36 parts of water. The pressure-reducing and injection-enhancing agent according to the present disclosure is characterized by having multiple functions in one agent. When used in an amount being 0.5% of the water injected to a water injection well, it shows excellent anti-swelling property, shrinking property, anti-corrosive property, and calcium sulfate and barium (strontium) sulfate scale resistance.

The present disclosure provides a pressure-reducing and injection-enhancing anti-scaling agent for low-permeability water-injection wells and a preparation method thereof. The anti-scaling agent is prepared from starting materials comprising: 10 to 12 parts of non-ionic surfactant(s), 18 to 20 parts of hexasodium triethylenetetramine-N,N,N,N,N,N-hexaacetate, 5 to 8 parts of anionic surfactant(s), 6 to 8 parts of an organic phosphonic acid-carboxylic acid scale inhibitor, 2 to 5 parts of a dispersant, 15 to 18 parts of a diluent, 8 to 10 parts of an organic amine salt, and 30 to 36 parts of water. The pressure-reducing and injection-enhancing agent according to the present disclosure is characterized by having multiple functions in one agent. When used in an amount being 0.5% of the water injected to a water injection well, it shows excellent anti-swelling property, shrinking property, anti-corrosive property, and calcium sulfate and barium (strontium) sulfate scale resistance.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

This invention concerns a method of synthesizing Azelaic Acid. Particular reference is made to providing a new synthetic process for preparing azelaic acid in large scale with high purity (e.g., >99.7% with any individual impurity not more than 0.1%), which can be used as an active pharmaceutical ingredient.

This invention concerns a method of synthesizing Azelaic Acid. Particular reference is made to providing a new synthetic process for preparing azelaic acid in large scale with high purity (e.g., >99.7% with any individual impurity not more than 0.1%), which can be used as an active pharmaceutical ingredient.